OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or “the Company”) (NASDAQ: OCS) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Oculis claimed that its Phase 3 DIAMOND trials were “advancing as planned,” but then announced on May 29, 2026, that both DIAMOND trials failed to meet their primary endpoints. The Company added that based on these results, it would not pursue an FDA filing for its drug candidate.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [e-mail].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.